You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
眾生藥業(002317.SZ):全資子公司獲得普拉洛芬滴眼液藥品註冊證書
格隆匯 05-27 18:42

格隆匯5月27日丨眾生藥業(002317.SZ)公佈,公司全資子公司廣東華南藥業集團有限公司於近日收到國家藥品監督管理局核准簽發的普拉洛芬滴眼液《藥品註冊證書》。

普拉洛芬屬於丙酸類非甾體抗炎藥,其作用機制為主要抑制環氧合酶(COX)活性,阻斷二十碳四烯酸衍生物的合成,抑制前列腺素的合成,緩解炎症反應。普拉洛芬滴眼液適應症為外眼及眼前節炎症的對症治療(眼瞼炎、結膜炎、角膜炎、鞏膜炎、淺層鞏膜炎、虹膜睫狀體炎、術後炎症)。

公司產品普拉洛芬滴眼液以化學藥品註冊分類4類獲批上市,標誌着此產品視同通過化學仿製藥一致性評價。

根據米內網數據庫顯示,普拉洛芬滴眼液2021至2023年在中國城市公立醫院銷售額分別為人民幣56,742萬元,52,577,63,749萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account